Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun 8;115(6):766-767.
doi: 10.1093/jnci/djad045.

RE: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)

Shan Song  1
Affiliations
Comment

RE: COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)

Shan Song. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

None reported.

Comment in

  • Response to Song.
    Korde LA, Best AF. Korde LA, et al. J Natl Cancer Inst. 2023 Jun 8;115(6):768. doi: 10.1093/jnci/djad054. J Natl Cancer Inst. 2023. PMID: 36975602 Free PMC article. No abstract available.

Comment on

References

    1. Korde LA, Best AF, Bowman M, et al. COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS) [published online ahead of print January 25, 2023]. J Natl Cancer Inst. 2023;djad015. doi: 10.1093/jnci/djad015. - DOI - PMC - PubMed
    1. World Health Organization. An international randomised trial of candidate vaccines against COVID-19. https://www.who.int/publications-detail/an-international-randomised-tria.... Accessed May 28, 2020.
    1. Navarro EA, Juan M, Urbano-Ispizua Á, Delgado J, et al. Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell therapy in B-cell malignancies. J Natl Cancer Inst. 2022;114(3):436-445. doi: 10.1093/jnci/djab194. - DOI - PMC - PubMed
    1. Frey N, Porter D.. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123-e127. doi: 10.1016/j.bbmt.2018.12.756. - DOI - PubMed
    1. Levin MJ, Ustianowski A, De Wit S, et al. ; PROVENT Study Group. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. - DOI - PMC - PubMed